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Methods Major eligibility criteria were histologically 
confirmed diagnosis of MPM, including clinical subtypes 
T0–3, N0–2, M0 disease; no prior treatment for the disease; 
age 20–75 years; Eastern Cooperative Oncology Group 
performance status 0 or 1; predicted postoperative forced 
expiratory volume >1000 ml in 1 s; written informed con-
sent. Treatment methods comprised induction chemother-
apy using pemetrexed (500 mg/m2) plus cisplatin (60 mg/
m2) for three cycles, followed by EPP and postoperative 
hemithoracic radiation therapy (54 Gy). Primary endpoints 
were macroscopic complete resection (MCR) rate for EPP 
and treatment-related mortality for TMT.
Results Forty-two eligible patients were enrolled: median 
age 64.5 (range 43–74) years; M:F = 39:3, clinical stage 
I:II:III = 14:13:15; histological type epithelioid were sar-
comatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 
completed EPP with MCR and 17 completed TMT. The 
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trial met the primary endpoints, with an MCR rate of 71 % 
(30/42) and treatment-related mortality of 9.5 % (4/42). 
Overall median survival time and 2-year survival rate for 42 
registered patients were 19.9 months and 42.9 %, respec-
tively. Two-year relapse-free survival rate of 30 patients 
who completed EPP with MCR was 37.0 %.
Conclusion This phase II study met the predefined 
primary endpoints, but its risk/benefit ratio was not 
satisfactory.
Keywords Mesothelioma · Clinical trials · Pleural 
disease · Thoracic surgery
Introduction
Malignant pleural mesothelioma (MPM) is a rare and 
locally aggressive tumor with a median survival time 
(MST) of 9–12 months [1]. MPM is associated with 
asbestos exposure, and its incidence is highly correlated 
with asbestos exposure, with a latency of 30–40 years [2]. 
The incidence of this disease peaked around 2004 in the 
United States and will peak from 2015 to 2020 in Europe 
and Australia [3]. However, in Japan, the peak may occur 
from 2030 to 2035 because of a historical delay in the 
heavy use of asbestos [4, 5]. High asbestos exposure in 
developing countries, particularly in Asia, is likely to 
cause future disease; however, this is difficult to quantify 
[6, 7].
Treating MPM is challenging. Extrapleural pneumo-
nectomy (EPP) is performed with curative intent, but the 
outcome is not acceptable in patients treated with surgery 
alone. Accordingly, the curative strategy in patients with 
resectable MPM shifted to trimodality therapy (TMT), 
which comprises induction chemotherapy followed by EPP 
and radiation therapy (RT). Evidence from studies con-
ducted in North America and Europe on TMT suggests that 
this strategy is feasible but has a poor risk-to-benefit ratio. 
Here we report the results of the Japan Mesothelioma Inter-
est Group (JMIG) 0601 Trial, a prospective multi-institu-




Patients were eligible [8] if they had a histologically con-
firmed diagnosis of MPM that was considered resectable, 
including all subtypes and clinical stage T0-3, N0-2, M0 
disease, according to the International Mesothelioma Inter-
est Group (IMIG) Staging System [9]. Other requirements 
were as follows: age between 20 and 75 years; an East-
ern Cooperative Oncology Group (ECOG) performance 
status of 0–1; adequate bone marrow, hepatic, renal, car-
diac, and respiratory functions; a predicted postoperative 
forced expiratory volume of ≥1000 ml in 1 s; and written 
informed consent. Existence of a measurable lesion was not 
mandatory. Exclusion criteria included any prior treatment 
for MPM, and serious systemic complications, including 
poorly controlled diabetes or hypertension, active infec-
tious disease, interstitial pneumonia or lung fibrosis, simul-
taneous or two metachronous (within 5 years) cancers, 
serious drug allergy or hypersensitivity to any drugs, preg-
nancy or breastfeeding, and grade 2 or greater peripheral 
neuropathy at registration. The ethics committee of each 
participating center approved the protocol before patients 
were enrolled.
Endpoints
The primary endpoints comprised macroscopic complete 
resection (MCR) rate by EPP and treatment-related mortal-
ity. MCR was defined as surgical removal of all gross tumor 
tissue [10]. Treatment-related death (TRD) was defined as 
any death occurring within 84 days after cessation or com-
pletion of TMT not related to disease progression. Second-
ary endpoints were proportion of patients who completed 
TMT, incidence of adverse events (AEs) during TMT, 
response rate for induction chemotherapy, 2-year overall 
survival rate of all eligible patients, and 2-year relapse-free 
survival (RFS) of patients with MCR.
Therapeutic regimens
The treatment protocol of this study comprised induc-
tion chemotherapy followed by surgery and adjuvant 
radiotherapy.
Chemotherapy
Induction chemotherapy consisted of three cycles of pem-
etrexed (500 mg/m2) followed by cisplatin (60 mg/m2) on 
day 1 and was given every 21 days. Folic acid (0.5 mg per 
day, orally) and vitamin B12 (1 mg intramuscularly every 
9 weeks) were administered 1–3 weeks before the first 
dose of chemotherapy and continued throughout induc-
tion chemotherapy. Dose adjustments were required for 
renal and nonhematologic toxicity as well as hematologic 
effects. A dose delay up to 42 days was permitted for 
recovery from drug toxicity. Tumor response was assessed 
using computed tomography (CT) after completion of 
induction chemotherapy using a modified version of the 
Response Evaluation Criteria in Solid Tumors (mRE-
CIST) [11].
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Surgery
EPP was performed within 42 days following the last dose 
of induction chemotherapy unless there was progression 
of disease or deterioration of organ functions that would 
make the surgery intolerable. EPP was defined as an en 
bloc resection of the entire pleura and the ipsilateral lung, 
with resection of the ipsilateral diaphragm, pericardium, 
or both, if required [12]. A systematic hilar and mediasti-
nal lymphadenectomy was preferred. Protocol treatment 
was terminated for patients with unresectable tumor at 
thoracotomy.
Radiotherapy
Adjuvant hemithoracic RT was performed within 12 weeks 
after surgery according to the methods described by Rusch 
et al. [13]. Patients received three-dimensional confor-
mal RT using a linear accelerator that delivered 6–20 MV 
photon and electron beams. A total dose of 54 Gy in 30 
fractions of 1.8 Gy/day was delivered. The clinical target 
volume (CTV) included the entire ipsilateral hemithorax 
pleural space and chest-wall incisions. If regional lymph 
nodes were involved, CTV included mediastinal lymph 
nodes. The planning target volume (PTV) included the 
CTV and a margin around the CTV to compensate for 
errors in treatment setup and internal target motion during 
treatment. Cerrobend blocks limited the dose to the liver, 
heart, and stomach, and electrons were used in blocked 
regions to dose the diaphragm and chest wall adequately. 
The spinal cord was protected for doses >41.4 Gy. The 
dose–volume planning objectives defined for the organs 
at risk were as follows: contralateral lung, percentage of 
volume receiving 5 Gy (V5) <50 %, V20 <7 %; liver, V20 
<50 %; heart, V45 <50 %; kidney, V15 <20 %; spinal cord, 
maximum dose <48 Gy. Intensity-modulated RT was not 
allowed in this study.
Evaluation
When TMT was completed or when protocol treatment 
ceased, patients underwent a physical examination and chest 
radiography/CT scans every 3 months up to 3 years or until 
death. If recurrence of MPM was suspected, appropriate 
examinations were performed. Major complications caused 
by chemotherapy, surgery, or RT were scored according to 
the National Cancer Institute Common Terminology Crite-
ria for Adverse Events version 4.0 guidelines [14].
Study design and statistical methods
Sample size was determined according to the results of an 
exact binominal test for MCR rate (%MCR). The target 
size of 40 eligible patients assured a statistical power of 
approximately 0.90 when expected and acceptable lowest 
%MCRs were 70 and 50, respectively, with a one-sided 
level of 0.10. Treatment-related mortality of 10 % was con-
sidered as the acceptable upper limit. Termination of the 
study was planned if the total number of TRDs reached 
five, indicating that a point estimate for treatment-related 
mortality exceeded 10 % of the planned sample size. 
Interim analyses were performed according to the Bayes-
ian predictive probability for %MCR. SAS version 9.2 
(SAS Institute Inc, Cary, NC, USA) and GraphPad Prism 
version 6.0 for Windows (GraphPad Software, San Diego, 
CA, USA) were used for analyses. A P value of <0.05 was 
considered statistically significant.
Study monitoring
The Data and Safety Monitoring Committee independently 
monitored protocol compliance and study progress and 
reviewed interim analysis reports. The study was registered 
at the University Hospital Medical Information Network 




Forty-two patients were enrolled from 12 institutions in 
Japan between May 2008 and November 2010. All patients 
were eligible. Patients’ characteristics are shown in Table 1. 
The Consolidated Standards of Reporting Trials (CON-
SORT) diagram is summarized in Fig. 1.
Chemotherapy
Neoadjuvant chemotherapy was started in 42 patients 
and discontinued in three because of progressive disease 
(n = 1), AE (n = 1), or both (n = 1). The remaining 39 
patients completed three courses of induction chemother-
apy without requiring any dose reduction. Thus, the chem-
otherapy completion rate was 92.9 % (39/42). There was 
one case with grade 4 toxicity of neutropenia (Table 2). 
Grade 3 toxicity was observed in seven patients. There 
were no chemotherapy-induced deaths. According to the 
mRECIST criteria, 14 patients achieved partial remission 
(PR), 19 had stable disease (SD), and seven had progres-
sive disease (PD). Two patients were not evaluable because 
they had no radiologically evaluable lesions. Response and 
disease-control rates were 33.3 % [95 % confidence inter-
val (CI) 19.6–49.6 %] and 78.6 % (95 % CI 63.2–89.7 %), 
respectively.
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Surgery
Of the 39 patients who completed chemotherapy, six did 
not proceed to EPP because of progressive disease (n = 4), 
AE (n = 1), or protocol violation (n = 1). EPP was started 
in 33 patients and was completed in 30 (14 right sided, 16 
left sided). These 30 patients achieved MCR with recon-
struction of the diaphragm (n = 2), pericardium (n = 2), 
or both (n = 26). EPP was abandoned in three patients 
because of extensive chest wall invasion (n = 2) or trans-
mural pericardial invasion (n = 1). Accordingly, the MCR 
rate was 71.4 % (30/42). Median operation time and blood 
loss in completed EPP cases (n = 30) were 437 (range 
335–655) min and 1461 (range 390–4530) g, respectively.
There were four TRDs, and all occurred within 84 days 
after EPP (Table 3). One patient died of bronchopleural 
fistula, empyema, and acute respiratory disease syndrome 
(ARDS) on postoperative day (POD) 30. Another patient 
developed cardiac herniation and hemothorax on POD 23 
and died on POD 80. Two patients died of ARDS on PODs 
61 and 72.
Postoperative complications are summarized in Table 4. 
Grade 3 or greater postoperative complications occurred 
Table 1  Patient characteristics
a Patients who completed extrapleural pneumonectomy (n = 30)





 Male 39 92.9
 Female 3 7.1
Location
 Right 19 45.2
 Left 23 54.8
Histology
 Epithelial 28 66.7
 Sarcomatoid 1 2.4
 Biphasic 9 21.1
















Fig. 1  Consolidated Standards of Reporting Trials (CONSORT) dia-
gram of registered patients. Of 42 registered patients, 33 underwent 
surgery. Three patients underwent exploratory thoracotomy because 
of unexpected extensive disease, and the remaining 30 completed 
extrapleural pneumonectomy (EPP) achieved macroscopic complete 
resection (MCR). Nineteen patients who underwent EPP started radi-
otherapy (RT), which was completed by 17
Table 2  Chemotherapy-related adverse events
Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
 Neutropenia 8 4 1 1
 Thrombocytopenia 2
Nonhematologic
 Nausea/appetite loss 23 11 2
 Vomiting 4 2 1
 Fatigue 8 3
 Diarrhea 2
 Constipation 9
 Febrile neutropenia 1
 Dyspnea 3
 Neurologic disorder 2 1
 Hiccup 6 1
 Radiculopathy 1
 Liver dysfunction 1 1
 Hyperglycemia 2
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in 21 of 33 patients (63.6 %). Arrhythmia occurred in 11 
(33.3 %) but was not critical in all cases. Bronchopleural 
fistula developed in three patients who underwent right-
sided EPP.
Radiation
Of the 30 patients with MCR, 11 did not proceed to RT 
because of AEs (n = 7), tumor relapse (n = 2), protocol 
violation (n = 1), or personal decision (n = 1). Of the 19 
patients who started RT, two discontinued because of AE 
(n = 1) or refusal (n = 1). Accordingly, TMT was com-
pleted in 17 (40.5 %, n = 42) patients. Grade 3 toxicity 
related to RT occurred in four patients (Table 5). There 
were no patients with grade ≥4 AEs or grade ≥3 radiation 
pneumonitis or interstitial pneumonia.
Histology
Preoperative histological diagnosis of epithelioid MPM 
was revised to biphasic MPM postoperatively for two 
out of 30 patients who completed EPP. In the other three 
patients with a preoperative diagnosis of undetermined 
MPM, two were diagnosed as having sarcomatoid and one 
as having epithelioid MPM.
Survival, RFS, and recurrence
The median follow-up period was 19.9 months after reg-
istration. MST and the 2-year survival rate for all regis-
tered patients (n = 42) were 19.9 (95 % CI 14.2–27.3 %) 
Table 3  Treatment-related 
deaths (n = 4)
AE adverse event, EPP extrapleural pneumonectomy, PR partial response, SD stable disease, ARDS acute 
respiratory distress syndrome
Patients 1 2 3 4
Age 66 72 69 72
Sex Male Male Male Male
Side Right Right Right Left
Histology Epithelioid Epithelioid Intermediate Biphasic
Clinical stage II I III III
Asbestos exposure None Yes Yes Yes
Smoking (pack-year) 34 0 0 50
Preoperative risks None Atrial fibrillation None None
Response to chemotherapy PR SD PR SD
Operation time (min) 362 439 366 410
Operative blood loss (g) 760 3950 390 4360
AE ARDS ARDS BPF, ARDS Cardiac herniation
AE onset (days after EPP) 41 28 4 23
Death (days after EPP) 61 72 30 80
Table 4  Surgery-related adverse events
ARDS acute respiratory distress syndrome








ARDS/interstitial pneumonia 1 2
Dyspnea 4 2 1 2
Bleeding/hemothorax 1 2 1






Table 5  Radiation-related adverse events
Adverse event Grade 1 Grade 2 Grade 3 Grade 4




Dermatitis 7 3 1
Fatigue 7 4 2
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and 42.9 % (95 % CI 27.8–57.1 %) months, respectively 
(Fig. 2a). MST and the 2-year survival rate of patients who 
completed EPP (n = 30) were 22.7 months and 50.0 %, 
respectively, and those for non-EPP patients (n = 12) were 
17.1 months and 25.0 %, respectively (Fig. 3).
Among the 30 patients who completed EPP with 
MCR, 19 relapsed postoperatively, with a median RFS of 
11.0 (95 % CI 2.2–31.5 %) months; RFS rates 1 and 2 years 
after surgery were 57.6 and 37.0 %, respectively (Fig. 2b). 
Relapse occurred at ipsilateral pleural effusion/chest wall 
(n = 8), mediastinum/pericardial effusion (n = 7), con-
tralateral lung parenchyma (n = 2), ascites (n = 3), lymph 
nodes (n = 3), and unknown (n = 1). Of 17 patients who 
completed TMT, relapse occurred in 11 at ipsilateral pleural 
effusion/chest wall (n = 5), mediastinum/pericardial effu-
sion (n = 2), contralateral lung parenchyma (n = 2), and 
ascites (n = 2). Significantly longer survival was observed 
in patients with a preoperative diagnosis of epithelioid his-
tology compared with nonepithelioid histology (MST 27.3 
vs. 13.6 months, P = 0.0013), and there were no statisti-
cally significant differences in survival according to other 
preoperative variables, such as age, gender, side, histology, 
clinical stage, and radiological response to chemotherapy.
There was no statistically significant survival difference 
correlated with pathological T/N factors and pathologi-
cal stage. Significantly longer survival was observed for 
patients who completed TMT (n = 17) in comparison with 
patients who completed EPP but not TMT (n = 13) (MST 
39.4 vs. 11.4 months, P = 0.0243) (Fig. 4).
Discussion
To date, several prospective studies have been conducted in 
North America and Europe in which MPM was treated by 
neoadjuvant chemotherapy followed by EPP and hemitho-
racic RT [15–21]. Treatment regimen in the study reported 
here was almost equivalent to that employed by the North 
American [19] and European [20] studies, with exception 
of cisplatin dose (Table 6, online only). Cisplatin dose of 
60 mg/m2 used here was based on results of studies con-
ducted in Japan for MPM treatment [22, 23]. Because 
Fig. 2  Survival. a Kaplan–Meier analysis of the overall survival of 
42 intent-to-treat (ITT) patients [median 19.9 months; 95 % con-
fidence interval (CI) 14.2–27.3 months]. b Relapse-free survival 
(RFS) of extrapleural pneumonectomy (EPP) patients. Median RFS 
of patients who completed EPP with macroscopic complete resection 
(MCR) was 11.0 months (95 % CI 2.2 %–31.5 % months). RFS rate 
2 years after surgery was 57.6 %
Fig. 3  Comparison of Kaplan–Meier overall survival analyses of 
extrapleural pneumonectomy (EPP) versus non-EPP patients. No 
significant difference was observed (median 22.7 months for EPP 
patients vs. 17.1 months for non-EPP patients)
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efficacy and safety of the combination of cisplatin and 
other drugs were assessed and confirmed in those stud-
ies, we administered cisplatin intravenously (60 mg/m2) in 
combination with pemetrexed.
The aims of our study were to determine whether TMT 
for MPM was feasible in Japan. Although all 12 participat-
ing institutions are leading treatment centers in Japan, none 
had experienced >20 cases of EPP during the 5 years prior to 
entering this study. Because the two primary endpoints were 
met here, we verified that TMT for MPM is feasible in Japan. 
Completion rates of induction chemotherapy, EPP, and MCR 
were comparable with those of the US trial [19] and EORTC 
08031 [20]. However, there are striking differences in the 
number of patients who failed to proceed to RT after comple-
tion of EPP, e.g., 26 % of the intent-to-treat (ITT) population 
in the study presented here versus 13 and 7 % in the US trial 
and EORTC 08031, respectively. This may be explained by 
the less stable condition of our patients after surgery, reflect-
ing less experience with TMT of the participating Japanese 
centers. Racial differences in resistance to highly aggressive 
treatment between Japanese and Caucasians may explain the 
different outcomes as well [24]. However, this argument is 
hardly convincing, because mortality due to pneumonectomy 
in patients with lung cancer in Japan [25] is approximately 
one third of that in the US [26] or UK [27].
Another aim of the study was to determine whether sur-
vival after TMT of Japanese patients with MPM was com-
parable with that of Caucasian patients. MST and RFS in 
this study were comparable with those of previous studies, 
notwithstanding the lower rate of TMT completion. This 
may partly indicate that MST of patients who completed 
TMT was longer in this study (39.4 months) compared 
with that of patients in US (29.1 months) [19] and Euro-
pean (33.0 months) [20] studies. However, the role of RT 
remained unclear, since the relapse pattern was similar in 
patients with or without RT in this study.
The study reported here verifies that TMT in patients 
with MPM is feasible in Japan, with similar survival and 
risk rates compared with those conducted in North Amer-
ica and Europe. However, it should be emphasized that the 
risk-to-benefit ratio in our study, as well as in the US/Euro-
pean studies, is not satisfactory.
Several centers tend to choose pleurectomy/decortica-
tion (P/D) instead of EPP as curative-intent surgery [28]. 
This trend appears to be related to the following situation: 
EPP is disadvantageous because of its high risk and occur-
rence of postoperative cardiopulmonary deterioration [29, 
30], and it only provides comparable postoperative survival 
with P/D [31, 32]. Note that the narrative above is based 
on retrospective nonrandomized studies because there is no 
prospective randomized study that directly compares EPP 
and P/D. Furthermore, there are very few completed pro-
spective phase II studies of P/D [33, 34].
In this context, the JMIG 1101 Trial, a multi-institutional, 
single-arm, feasibility study of induction pemetrexed plus 
cisplatin followed by P/D was conducted in Japan [35], and 
patient recruitment was completed by January 2014. Although 
a direct comparison of results of JMIG 1101 and our study is 
not appropriate, it may provide valuable information regarding 
the choice between EPP and P/D because both studies are con-
ducted and pursued with very similar backgrounds.
In conclusion, this prospective phase II study demon-
strates that TMT for MPM meet the primary endpoints but 
its risk:benefit ratio is not satisfactory.
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Fig. 4  Significantly longer survival was observed for patients who 
completed trimodality therapy (TMT) (n = 17) in comparison with 
patients who completed extrapleural pneumonectomy (EPP) but not 
TMT (n = 13)
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